A Clinical Safety and Efficacy Study in Subjects With Overweight or Obese Class - I, to Evaluate the Degree of Significant Weight Loss by Regular Intake of Phaseolean (White Kidney Bean Standardized Extract)
NCT ID: NCT05711784
Last Updated: 2024-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
66 participants
INTERVENTIONAL
2023-02-22
2023-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is dose-response study to evaluate effectiveness of two different dosage i.e. 1500 mg Versus 3000 mg.
22 subjects will be enrolled per test treatment to complete 20 subjects per test treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Investigate Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of JNJ-54175446 in Healthy Participants
NCT02475148
A Food Effect Study in Healthy Volunteers With Belzutifan (PT2977, MK-6482) Tablets
NCT03445169
A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults
NCT05349864
A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649
NCT02151617
Effect of Different Dosages of Paraxanthine, the Major Caffeine Metabolite, on Energy and Focus
NCT06117280
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study is dose-response study to evaluate effectiveness of two different dosage i.e. 1500 mg Versus 3000 mg.
22 subjects will be enrolled per test treatment to complete 20 subjects per test treatment.
The potential subjects will be screened as per the inclusion \& exclusion criteria only after obtaining written informed consent from the subjects. The subjects will be instructed to visit the facility as per the below visits.
* Visit 01 (Within 30 Days): Screening, Baseline evaluations
* Visit 02 (Day 01): Enrolment \& Treatment phase start
* Visit 03 (Day 21): Treatment Period, Evaluations
* Visit 04 (Day 45): Treatment Period, Evaluations \& End of Study Visit
* Telephonic follow-up will be taken thrice a week (Monday, Wednesday and Friday) during an entire study to check compliance with the diet plan and study treatment.
Subjects will be pre-screened by the screening department of NovoBliss Research. Subjects will be telephonically contacted by recruiting department prior to the enrolment visit. Subjects will be instructed during screening (prior to enrolment) not to consume any weight-loss medications, or supplementation or topical anti-cellulite treatment during the study.
Eligible subjects will be randomly assigned equally to one of three groups in a 1:1:1 ratio as follows:
* Arm A (Treatment A): Subjects will be given a test treatment of 1500 mg/day (2 capsules in the morning before breakfast, 2 capsules in the afternoon before lunch and 2 capsules at night before dinner; each capsule containing 250 mg Phaseolean (White Kidney Bean Standardized Extract) along with the diet regimen and exercise as advised by the clinical nutritionist /Dietician (Diet of 2000 kcal/day throughout the study and walking exercise for 45 mins daily for consecutive 45 Days).
* Arm B (Treatment B): Subjects will be given a test treatment of 3000 mg/day (2 capsules in the morning before breakfast, 2 capsules in the afternoon before lunch and 2 capsules at night before dinner; each capsule containing 500 mg Phaseolean (White Kidney Bean Standardized Extract) along with the diet regimen and exercise as advised by the clinical nutritionist /Dietician (Diet of 2000 kcal/day throughout the study and walking exercise for 45 mins daily for consecutive 45 Days).
* Arm C (Treatment C): Subjects will be given placebo capsules (2 capsules in the morning before breakfast, 2 capsules in the afternoon before lunch and 2 capsules at night before dinner; each capsule containing 250 mg Resistant Dextrin as Placebo along with the diet regimen and exercise as advised by the clinical nutritionist /Dietician (Diet of 2000 kcal/day throughout the study and walking exercise for 45 mins daily for consecutive 45 Days).
Subjects will be followed up as per the schedule of assessments. Assessment of efficacy parameters will be done before test treatment usage on Day 1, and will be compared with after test treatments usage on Day 21 (+2 Days), \& Day 45 (+2 Days) within treatments and between treatments as listed below.
* Anthropometry: Height, Weight, Body Mass Index (BMI), Hip and Waist Circumference
* Skinfold fat thickness
* Maximum Oxygen consumption (VO2)
* Vitals (Heart Rate, Blood Pressure)
* ECG and Chest X-Ray
* Blood Biochemical Parameters (Serum albumin, total protein, AST, ALT, glucose, BUN, uric acid, creatinine levels, Random Insulin)
* Biomarkers - Amylase, Lipid Profile, HbA1c
* Hedonic Questionnaires - about product perception and consumer feedback (Weight reduction, feeling of the light weight of the body, reduction of Hip and Waist circumference, reduction in skinfold fat thickness, hunger feeling, satiety level etc.)
* Digital Photographs: Body photographs with measurement of waist and hip circumference - before test treatment usage and after test treatment usage
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
DOUBLE
The Investigator/Evaluator will be blinded to the randomization schedule. The sequence number as per the randomization schedule will be used as Randomization ID.
Subjects will be randomly allocated to one of the three treatment groups, as per the randomization code. Neither the subject nor the Investigator/Evaluator shall be aware of the treatment allocation (Double Blind). To maintain blinding, the study staff who involves in treatment dispensing and distribution will not be involved in any other study-related activities.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phaseolean (White Kidney Bean Standardized Extract)1500 mg Capsules
Phaseolus Vulgaris L. is rich in alpha-amylase and alpha-glucosidase inhibitor. It has been used for calories absorption through preventing or delaying the digestion of complex carbohydrate.
Phaseolean (White Kidney Bean Standardized Extract) 1500 mg Capsules
Mode of Usage: 2 capsules each time before 3 daily meals for consecutive 45 days.
Route of Administration: Oral Administration with a glassful (approx. 250 mL) of water.
Phaseolean (White Kidney Bean Standardized Extract)3000 mg Capsules
Phaseolus Vulgaris L. is rich in alpha-amylase and alpha-glucosidase inhibitor. It has been used for calories absorption through preventing or delaying the digestion of complex carbohydrate.
Phaseolean (White Kidney Bean Standardized Extract)3000 mg Capsules
Mode of Usage: 2 capsules each time before 3 daily meals for consecutive 45 days.
Route of Administration: Oral Administration with a glassful (approx. 250 mL) of water.
Placebo (Resistant Dextrin) Capsules
Resistant dextrin is a soluble fiber, derived from wheat or corn starch and is prepared by highly controlled partial hydrolysis and repolymerization of the dextrinization process
Placebo (Resistant Dextrin) Capsules
Resistant dextrin is a soluble fiber, derived from wheat or corn starch and is prepared by highly controlled partial hydrolysis and repolymerization of the dextrinization process
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Phaseolean (White Kidney Bean Standardized Extract) 1500 mg Capsules
Mode of Usage: 2 capsules each time before 3 daily meals for consecutive 45 days.
Route of Administration: Oral Administration with a glassful (approx. 250 mL) of water.
Phaseolean (White Kidney Bean Standardized Extract)3000 mg Capsules
Mode of Usage: 2 capsules each time before 3 daily meals for consecutive 45 days.
Route of Administration: Oral Administration with a glassful (approx. 250 mL) of water.
Placebo (Resistant Dextrin) Capsules
Resistant dextrin is a soluble fiber, derived from wheat or corn starch and is prepared by highly controlled partial hydrolysis and repolymerization of the dextrinization process
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Sex: Healthy non-pregnant/non-lactating females and Males.
3. Female of childbearing potential must have a reported negative pregnancy during screening and the end of the study.
4. Subject is generally in good health and willing to reduce weight.
5. Overweight to Obese Class - I, BMI between or equal to 25 to 35 kg/m2, or total fat percentage reaching: men \> 25% and women \> 30% using Karada Scan.
6. Willing to observe dietetic plan in accordance with dietitian evaluation,
7. Able and willing to participate in the study by complying with the protocol procedures.
8. Subject is willing to forgo liposuction procedures or any weight loss therapy 3 months prior to and for the duration of the study.
9. Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.
10. If the female subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.
11. If currently using hormonal contraception, has been using this form of contraception for at least 6 months and agrees to continue using the same contraception for the duration of the study.
12. Subject is willing to participate in exercise program (Daily, 45 mins brisk walking for consecutive 45 Days of treatment period) and recording to subject diary card.
13. Subject is willing to come in fasting state for every study visit.
14. Subject is agree to consume a vegetarian/non-vegetarian diet of approximately 2000 kcal/day (14% protein, 25%Fat and 61% carbohydrate).
15. Subject is willing to give written informed consent and are willing to follow the study procedure
Exclusion Criteria
1. Subject has a history of allergy or sensitivity to the test treatments ingredients.
2. Subject who has a history of allergy with products containing beans, white kidney beans.
3. Subjects BMI is between less than 25 and greater than 35 kg/m2.
4. Subjects having past or present history or clinically significant findings indicating cardiovascular disease, type 2 diabetes mellitus, hypertension, endocrine, pulmonary, neurological or psychological disorders, hypo or hyperthyroidism and renal disorders.
5. Subjects having drug and alcohol abuse.
6. Smokers and tobacco users.
7. Subjects having more than 5 kg variation in body weight within 3 months before study entry.
8. Subjects using other weight loss medications, as well as stimulants, laxatives or diuretics taken solely for the purpose of weight loss.
9. Undergone surgery before 30 days of screening or planning to undergo surgery within the study period.
10. Subjects having chronic diarrhoeal disorders, cancer, hepatic dysfunction, and human immunodeficiency virus (HIV) infection.
11. Participation in other drugs, investigational medicinal product, any herbal products and/or cosmetics intended to weight loss clinical trials within 3 months before enrolment in this trial.
12. Any other diseases/co-morbidity that is considered by the Investigator as an exclusion.
13. With severe hepatic and/or renal impairment, liver enzyme level (ALT and/or AST) is greater than 2.5 times the upper normal limit.
14. Taking antibiotic therapy, anti-depressant treatment or treatment related to anxiety in the month preceding the study,
15. Taking anti-depressant treatment or treatment related to anxiety Subject in a state of depression.
16. Non-stable weight during the last 6 months (\>5% change in total weight)
17. Consuming food supplements or functional foods known to have an influence on weight management in the month preceding the inclusion and/or likely to take during the test
18. Following or having followed a hypocaloric diet (energy intake \<1,500 kCal/day) in the month preceding inclusion and/or likely to undertake this diet during the test.
19. Diagnosed eating disorders (bulimia, anorexia nervosa, vomiting),
20. Using topical anti-cellulite treatments
21. Pregnant or breastfeeding or planning to become pregnant during the study period.
22. Subject has a history of chronic illness which may influence the cutaneous state.
23. Subjects participating in other similar nutraceuticals, food, supplemental or therapeutic trials within the last four weeks.
24. Any other condition which could warrant exclusion from the study, as per the Investigator's discretion
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ambe Phytoextracts Pvt. Ltd
INDUSTRY
NovoBliss Research Pvt Ltd
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Nayan Patel
Principal Investigator - Medical Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr Nayan K Patel, MBBS
Role: PRINCIPAL_INVESTIGATOR
Medical Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NovoBliss Research Pvt Ltd
Ahmedabad, Gujarat, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NB220038-AG
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.